Miami, FL -- June 12, 2012-- Data presented at the Society for Nuclear Medicine (SNM) Annual Meeting shows that uptake of the investigational imaging agent [18F]flutemetamol correlates with a beta amyloid in vivo[i] biopsy and can be quantified using a PET-only registration method.
business unit
tags
Miami, FL -- January 17, 2012-- Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer's Disease (AD). [18F]Flutemetamol is a GE Healthcare PET imaging agent in phase III development for the detection of beta amyloid.
business unit
tags
Head of New Product Development for Medical Diagnostics Ger Brophy Gives Talk
Princeton, NJ, October 26, 2011 --Ger Brophy, PhD, Head of New Product Development, GE Healthcare, Medical Diagnostics discussed diagnostics as the future of personalized medicine at the TEDMED 2011 Conference in San Diego, CA. During his talk, Brophy noted that while new drugs and targeted treatment have advanced the personalized medicine field considerably, realizing this paradigm depends on the development of powerful diagnostics -- some of which are available today.